Editas Medicine, Inc.

Good morning and welcome to Editas Medicine's second quarter 2022 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Ron Moldover, Investor Relations at Editas Medicine.

Thank you, Paul. Good morning, everyone, and welcome to our second quarter 2022 conference calls. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available on the investor section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A. As a reminder, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our most recent annual report on Form 10-K, which is on file with the FCC as updated by our subsequent filing. In addition, Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. Now I will turn the call over to our Executive Chairman, Jim Mullin.

Thanks, Ron, and good morning, everyone. I'm joined today by several members of the Editas executive team, including Gilmore O'Neill, our chief executive officer, Mark Shearman, our chief scientific officer, Michelle Robertson, our chief financial officer, and Baesong Mei, who I am thrilled to welcome as our new chief medical officer. As you know, on June 1st, Gilmore assumed the role as CEO, and I became executive chairman of the board. Over the past two months, I've partnered closely with Gilmore and the executive team to ensure the seamless changeover of the CEO role. We are very fortunate to appoint a leader of Gilmore's caliber as CEO. During his nearly 20 years of experience in genetic medicine and clinical development, including senior leadership positions at Sarepta and Biogen, he has led some of biotech's most successful clinical programs. Gilmore's drug development experience, proven leadership, passion for genetic medicine, and focus on patients are exactly the right skill set and experience to lever the foundation we've built over the past several years and lead the company towards commercialization. If his first few months are any indication of his leadership abilities, Editas' next few years are undoubtedly poised for success. With that, I'm very pleased to turn the call over to our new CEO, Gilmore O'Neill.